None
Skip to mainIndia is likely to approve Emergency Use Authorisation for the Merck drug Molnupiravir in a few days time. Molnupiravir is an oral drug designed to block the replication of various RNA viruses, including the SARS-CoV-2 virus. The medicine is meant for adults who are at risk for progressing to severe COVID-19 or hospitalization. The medicine can be taken at home.
Dr Ram Vishwakarma, Chairman of the Covid Strategy Group, CSIR calling the drugs the "final nail in the coffin of the virus by science", said, "I think Molnupiravir will be already available to us. Five companies are sitting with the drug manufacturer... I think any day we will have approval of Molnupiravir"
Five Indian pharmaceutical companies had partnered to conduct a clinical trial of Merck (MSD)’s experimental antiviral candidate Molnupiravir to treat mild Covid-19 in an outpatient setting. The partners are Cipla, Dr Reddy’s Laboratories, Sun Pharmaceutical Industries and Torrent Pharmaceuticals.
Molnupiravir works by disrupting the virus’s reproduction. Once the virus gets inside the body’s cells, it replicates its genome, which is made not of DNA but RNA (ribonucleic acid). These replicated genomes are then formed into complete virus particles which burst out of the cell and continue to spread around the body. However, the molecules of molnupiravir are absorbed by virus-infected cells, where they are converted into a defective version of the building blocks of RNA. So, when the virus tries to replicate, the resulting virus particles have defective genetic material and can no longer reproduce. This means that the viral load should remain low, which reduces the risk of serious disease.
In India, it might initially cost "2000 to 3000 or 4000 rupees per cycle of treatment, then it will come down to 500 to 600 or 1,000 rupees.
🕑 02 Jul, 2025 10:03 AM
Commutation Relief In Sight? Panel Likely To Review 15-Year Deduction Rule
🕑 12 Jun, 2025 08:12 AM
8th Pay Commission: Uncertainty Looms as Employees Await Terms of Reference
🕑 24 Apr, 2025 10:21 PM
Staff Side constitutes panel for drafting memorandum to 8th CPC when formed
🕑 24 Apr, 2025 10:17 PM
8th Pay Commission likely to be set up by mid May
🕑 09 Apr, 2025 10:27 AM
Loan EMIs to get Cheaper as RBI cuts Repo Rate sgain | See the benefit
🕑 04 Apr, 2025 04:49 PM
AICPI-IW declines again, may affect DA hike in July 2025
🕑 02 Apr, 2025 08:27 AM
8th Pay Commission update: Standing Committee of NC-JCM to meet on April 23
🕑 09 Jun, 2025 08:25 AM
📢 UPS vs NPS: The Retirement Dilemma Facing 27 Lakh Government Employees
🕑 04 Apr, 2025 04:46 PM
NPS To UPS Switch from April 1: A Detailed Look at the Option to Switch
🕑 30 Mar, 2025 11:01 AM
8th Pay Commission implementation may get delayed till 2027 – Here’s why
🕑 27 Mar, 2025 10:25 PM
7th CPC wanted a permanent pay panel, end DA revision twice
🕑 27 Mar, 2025 08:43 AM
8th Pay Commission: What Kind Of Salary Hike Can Be Staff Expected?
🕑 20 Mar, 2025 08:24 AM
Why the commuted pension is restored after 15 years, not 12 years
🕑 17 Mar, 2025 08:37 AM
📈 Expected Dearness Allowance (DA) from January 2026 Calculator